Evotec receives milestone payment for start of second Phase II trial in its multi-target alliance with Bayer
In October 2012, Evotec and Bayer began their multi-target discovery alliance with the shared goal to discover three clinical candidates with a focus in the field of endometriosis. The successful and productive long-term alliance ended in 2018, generating six first-in-class pre-clinical candidates three of which have progressed into Phase I clinical trials. Bayer advanced a first programme into a Phase II trial in chronic cough in July 2018 and has now initiated a further candidate into a second Phase II trial for the same indication.
Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: “Our long-term alliance with Bayer represents our continued commitment to bring new therapeutics options to millions of patients. We are pleased to see a second compound from this alliance moving into Phase II studies for chronic cough, a debilitating condition affecting about ten percent of the global population and with no approved, curative therapy.”
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.